McKesson Co. (NYSE:MCK) Shares Purchased by Act Two Investors LLC

Act Two Investors LLC lifted its holdings in McKesson Co. (NYSE:MCK) by 2.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,073 shares of the company’s stock after purchasing an additional 178 shares during the period. McKesson makes up 0.8% of Act Two Investors LLC’s holdings, making the stock its 24th biggest holding. Act Two Investors LLC’s holdings in McKesson were worth $3,738,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MCK. Sachetta LLC acquired a new position in shares of McKesson in the fourth quarter valued at approximately $27,000. BKM Wealth Management LLC acquired a new position in shares of McKesson in the fourth quarter valued at approximately $31,000. WASHINGTON TRUST Co lifted its stake in McKesson by 42.5% in the fourth quarter. WASHINGTON TRUST Co now owns 114 shares of the company’s stock worth $53,000 after acquiring an additional 34 shares during the last quarter. Private Wealth Management Group LLC purchased a new position in McKesson in the fourth quarter worth approximately $60,000. Finally, Milestone Investment Advisors LLC purchased a new position in McKesson in the third quarter worth approximately $61,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Trading Up 0.5 %

MCK stock traded up $2.70 on Friday, hitting $560.73. The company’s stock had a trading volume of 512,352 shares, compared to its average volume of 810,789. The stock has a market cap of $72.89 billion, a price-to-earnings ratio of 25.05, a price-to-earnings-growth ratio of 1.31 and a beta of 0.45. The firm has a 50 day moving average of $538.64 and a two-hundred day moving average of $502.88. McKesson Co. has a 1 year low of $373.28 and a 1 year high of $566.16.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $6.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.34 by ($0.16). The firm had revenue of $76.36 billion during the quarter, compared to analyst estimates of $79.32 billion. McKesson had a net margin of 0.97% and a negative return on equity of 245.88%. The business’s quarterly revenue was up 10.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $7.19 earnings per share. As a group, equities analysts forecast that McKesson Co. will post 31.57 EPS for the current fiscal year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 1st. Shareholders of record on Monday, June 3rd will be paid a $0.62 dividend. The ex-dividend date is Monday, June 3rd. This represents a $2.48 annualized dividend and a yield of 0.44%. McKesson’s dividend payout ratio is currently 11.08%.

Insider Buying and Selling at McKesson

In other news, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Susan R. Salka sold 606 shares of the company’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $558.04, for a total transaction of $338,172.24. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the company’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total transaction of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at $22,789,074.75. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,080 shares of company stock valued at $2,160,489. 0.21% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MCK. StockNews.com upgraded shares of McKesson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 4th. SVB Leerink began coverage on shares of McKesson in a research note on Monday, February 26th. They issued an “outperform” rating and a $600.00 price target for the company. Evercore ISI lifted their price target on shares of McKesson from $590.00 to $600.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 8th. Wells Fargo & Company lifted their price target on shares of McKesson from $502.00 to $551.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 9th. Finally, Morgan Stanley boosted their price objective on shares of McKesson from $522.00 to $548.00 and gave the stock an “overweight” rating in a research report on Monday, April 15th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and an average price target of $571.47.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.